News Release

Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke

Peer-Reviewed Publication

R&D at British American Tobacco

A new in vitro study has revealed that nicotine and cotinine, a metabolite of nicotine, can potentially inhibit DNA damage caused by a certain carcinogen in smoke.

The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK is produced during the curing of tobacco leaves and ultimately ends up in the tobacco smoke. Once inhaled, it is metabolised in the lung and liver, where it is activated by a variety of enzymes called Cytochrome P450 (CYP). Previous research in mice has revealed that nicotine can partially interfere with the activation of NNK, and this has been corroborated by independent laboratory studies showing that nicotine and cotinine can inhibit purified CYP enzymes.

Now a new study by scientists at British American Tobacco and Vivotecnia in Madrid, Spain, has investigated what impact this inhibition of CYP activity by nicotine may have. The lead researchers, Patricia Ordonez and Ana Belen Sierra, incubated laboratory-grade liver cells (expressing CYP enzymes) with either NNK or NNKOAc, a form of NNK that is not affected by CYPs. They compared the effect of increasing doses of nicotine, or the nicotine metabolite cotinine, on DNA damage using the COMET technique*. Results were compared with controls.

The results show that doses of nicotine and cotinine similar to those found in the plasma of smokers inhibit the DNA strand breaks caused by NNK – but not by NNKOAc – in a dose-dependent manner. The results suggest that nicotine and cotinine can potentially protect against one form of DNA damage (DNA strand breaks) caused by NNK in vitro, and that they do this by inhibiting CYP enzymes.

'The study highlights the complex interactions between NNK and nicotine,' explains Emmanuel Minet, Senior Scientist at British American Tobacco. 'Tobacco smoke is an extremely complex mixture containing chemicals that are constantly reacting and interacting with each other in a way that may enhance or inhibit their toxicity,' he says. Clearly, therefore, there are limitations to assessing individual toxicants in tobacco smoke and other complex mixtures.

Typically, tobacco smoke carcinogens are evaluated individually, and NNK carcinogenicity has been clearly established in systems using doses of a single chemical. However, these findings illustrate that the risk associated with a particular toxicant may be relative to the presence of other chemicals.

Moreover, the findings raise an interesting and potentially controversial question regarding unanticipated effects of reducing nicotine in tobacco products: whether such reduction could lead to an increase of one form of nitrosamine-dependent DNA damage.

However, the researchers caution that the study was on immortalized liver cells – not those of the lung, which express different CYP enzymes. Furthermore, there is no evidence that nicotine or cotinine have a protective effect on DNA strand break in vivo. They also point out that strand breaks are only one of many mechanisms through which NNK can damage DNA and those have not been evaluated in the study. The next step is to repeat the experiment using human lung epithelial cells.


The results are published in Toxicology in Vitro (doi: 10.1016/j.tiv.2014.06.017)

Notes to Editors

About British American Tobacco:

British American Tobacco is the world's second largest stockmarket-listed tobacco group by global market share, with brands sold in over 180 markets and employing over 60,000 people. Leading global brands include Dunhill, Kent, Pall Mall and Lucky Strike.

About Vivotecnia:

Vivotecnia is a European Toxicology Safety Contract Research Organisation (CRO), ISO certified and GLP accredited with the Headquarters based in Madrid, Spain. Vivotecnia support the preclinical development of biotechnology and pharmaceutical products as well as safety studies for cosmetic and chemical companies.

About Tobacco Harm Reduction:

The only way to avoid the risks associated with tobacco use is not to consume tobacco at all, and the best way to reduce the risks is to stop using tobacco. However, the concept of harm reduction is increasingly being considered in relation to tobacco use and it is a key element of our business strategy and is being discussed by some regulators. Harm reduction is about finding practical ways to minimise the health impact of an inherently risky activity or behaviour, without seeking to stop it entirely. An example of harm reduction in action is the use of seat belts and airbags in cars. We think it's important to work towards producing consumer-acceptable, potentially reduced risk products. We believe that tobacco regulatory policies should include harm reduction approaches for the millions of adults globally who will continue to consume tobacco products.

*About the COMET assay:

The COMET assay is a technique used to quantify one form of DNA damage, DNA strand breaks, at the level of the individual eukaryotic cell. An electric current is applied to a gel matrix causing the migration of fluorescently labelled individual cell

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.